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Vinpocetine, a derivative of vincamine, widely used in the clinical pharmacotherapy
of cerebral circulatory diseases, inhibits retrograde axoplasmic transport of nerve
growth factor (NGF) in the peripheral nerve, resulting in transganglionic
degenerative atrophy (TDA) in the related ipsilateral superficial spinal dorsal horn,
as shown in our previous publications. TDA induced by vinpocetine has been
demonstrated to be followed by depletion of the marker enzyme fluoride-resistant
acid phosphatase (FRAP) and its isoenzyme thiamine monophosphatase (TMP), and
by the decrease in the pain-related neuropeptide substance P from laminae I–II–(III)
from the segmentally related, ipsilateral substance of Rolando of the spinal cord. In
the present paper, we report on the behavioral effects of perineurally administered
vinpocetine. Nociception, induced by intraplantar injection of formalin, was
mitigated by vinpocetine; increased expression of c-fos in the ipsilateral,
segmentally related upper dorsal horn was also prevented. Since vinpocetine is
not a microtubule inhibitor, and its chemical structure differs from that of vincristin
and vinblastin (used formerly by us in the therapy of intractable, chronic
neuropathic pain), its mode of action is enigmatic. We assume that the effect of
vinpocetine in blocking retrograde axoplasmic transport of NGF might be related to
its interaction with membrane trafficking proteins, such as signalling endosomes
and the endocytosis-mediating ‘‘pincher’’ protein. Temporary, locally restricted
decrease of nociception, induced by vinpocetine, might be useful in the clinicalElsevier GmbH. All rights reserved.
of the Hungarian Pain Society, 2006, and published in Abstract form in the official journal of the
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Vinpocetine and pain 141treatment of intractable, chronic neuropathic pain, since vinpocetine can success-
fully be applied by transcutaneous iontophoresis.
& 2007 Elsevier GmbH. All rights reserved.Introduction
According to Wall (1995), pain is the equivalent
of nociception transmitted to and perceived by the
cerebral cortex. At the level of the spinal cord,
central terminals of primary nociceptive neurons
terminate mostly in laminae I and II of the dorsal
horn, mainly in the form of scallopped terminals,
which contain the pain-related neuropeptide
substance P (SP) and the marker enzyme fluoride-
resistant acid phosphatase (FRAP) and its isoen-
zyme thiamine monophosphatase (TMP; Snyder and
McMahon, 1998).
It has been shown (Csillik, 1984; Csillik et al.,
1985) that blockade of retrograde axoplasmic
transport in a sensory nerve results in transganglio-
nic degenerative atrophy (TDA) of central terminals
of the affected primary nociceptive neurons.
Blockade of axoplasmic transport was achieved
formerly by perineural application of the micro-
tubule inhibitors vincristin and vinblastin. TDA,
causing an intermittent disruption of the nocicep-
tive pathway, resulted in temporary loss of pain in
the area supplied by the related sensory neurons.
Based on these findings, transcutaneous iontophor-
esis of vincristin and vinblastin was successfully
used in order to alleviate chronic pain deriving from
postherpetic neuralgia, toxic polyneuropathies and
terminal oncological states (see references in
Knyiha´r-Csillik et al., 2007a).
Since the transcutaneous application of vincristin
and vinblastin was not approved by health autho-
rities for fear of unforeseen side effects of
microtubule inhibitors, our interests were drawn
to another vinca alkaloid, vinpocetine, which is
proven to be devoid of any side effects (Keme´ny
et al., 2005). Vinpocetine, a derivative of vinca-
mine, is widely used in clinical pharmacotherapy
of various cerebral circulatory diseases (Bonoczk
et al., 2000), both per os and parenterally. In spite
of the fact that vinpocetine is not a microtubule
inhibitor and its chemical structure shows no
resemblance to that of vincristin, we found that,
at adequate concentration, vinpocetine inhibits
retrograde axoplasmic transport of nerve growth
factor (NGF), as shown by radiochemical studies
(Knyiha´r-Csillik et al., 2007a).
In this paper, the effect of perineural vinpocetine
treatment in a nociceptive model will be reported
on the basis of behavioral experiments and theexpression of c-fos, known to represent increased
synaptic activity. In addition, the mechanism of the
blockade of retrograde axoplasmic transport of
NGF induced by vinpocetine will be discussed in the
light of recent neurochemical investigations. On
these premises, the possibility of transcutaneous
iontophoresis of vinpocetine will be discussed for
the alleviation of chronic neuropathic pain.Experimental procedures
Investigations were performed on 15 young adult
male albino Wistar strain rats (Rattus norvegicus
albus) ranging from 200 to 250 g in body weight.
Care of the animals complied with the guidelines of
the Hungarian Ministry of Welfare; experiments
were carried out in accordance with the European
Communities Council Directive (November 24,
1986; 86/609/EEC) and the Guidelines for Ethics
in Animal Experiments of the Szeged University,
Albert Szent-Gyo¨rgyi Medical School. Vinpocetine
(eburnamine-14-carboxylic acid ethyl ester) was
obtained from Sigma-Aldrich (Saint Louis, MO,
USA), catalog number V 6383.
The pain behavioral effect of subcutaneous
formalin treatment was studied in eight rats by
means of the formalin test of Dubuisson and Dennis
(1977). A dilute formalin solution (10%, 10 mL) was
injected subcutaneously into the plantar surface of
a hind paw using a 27-gauge syringe needle. This
produced flinching, shaking and licking; the short-
lived acute phase is comparable to acute nocicep-
tion, while the second phase represents tonic pain.
The number of flinches+shakes of the injected paw
was counted each minute for a period of 60min.
The number of flinches+shakes was averaged
into 3-min periods, according to the technique
described by Butkevich et al. (2005). The immuno-
histochemical equivalent of perineural vinpocetine
treatment was assessed on the basis of c-fos
expression in the spinal cord of rats (Butkevich
et al., 2006). One hour after the behavioral testing,
rats were deeply anesthetized with chloral hydrate
and perfused transcardially with cold 4% parafor-
maldehyde buffered by 0.1M phosphate saline.
After perfusion, the lumbar spinal cord was excised
and post-fixed in the same fixative overnight. After
cryoprotection in an ascending series of sucrose,
15 mm serial frozen sections were cut in a cryostat.
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peroxide for 10min, processed for immunohisto-
chemical staining and incubated for 48 h at 4 1C in
rabbit anti-Fos (Calbiochem, CA), diluted 1:2000 in
PBS with Triton X. After rinsing, the sections
were transferred into the second antibody for 1 h
(goat anti-rabbit, Vector, Burlingame, CA) and
processed according to the ABC kit protocol. Visibly
labelled nuclei in the superficial dorsal horn
(laminae I and II) were counted in a 0.1mm2 square
and the mean number of c-fos expressing cells was
calculated by averaging seven sections.
In seven further rats, the sciatic nerve was first
enclosed in a Gelaspon cuff containing 106 M
vinpocetine; 72 h later a dilute formalin solution
(10%, 10 mL) was injected subcutaneously into the
plantar surface of the hind paw using a 27-gauge
syringe needle, and the number of flinches+shakes
of the injected paw was counted as in the control
experiments. The number of c-fos immunoreactive
nuclei was determined in a blinded manner andFigure 1. Numbers of flinchings, shakings and licking in a
unilateral formalin test (filled circles) and 3 days after
perineural application of vinpocetine (empty circles).
Number of animals tested was n ¼ 7 in both cases. The
difference between the two curves is significant
(po0.05).
Figure 2. Distribution of c-fos immunoreactive nuclei in segm
of the formalin test (apparent right). Number of c-fos immun
Note that the number of c-fos immunoreactive cells increased
formalin test.averaged as in controls. In evaluating the effects
of perineural vinpocetine treatment, the Mann–
Whitney test and Student’s t-test were used; for
repeated measures, ANOVA was employed. In the
graphical representation of the data obtained the
means7S.E.M. are illustrated. A value of po0.05
was considered statistically significant.Results
Subcutaneous injection of formalin into the
plantar surface of a hind paw induced redness and
swelling in the ipsilateral paw, followed by nume-
rous flinchings, shakings and licking (Figure 1, filled
circles). Perineural application of a Gelita tampon
sponge soaked in 106 M vinpocetine, 72 h prior to
formalin injection, did not affect redness and
swelling of the paw, but reduced the number of
flinchings, shakings and licking (Figure 1, empty
circles). Immunohistochemical investigations de-
monstrated significant differences in c-fos expres-
sion between control and vinpocetine-treated
animals. As shown in Figures 2 and 3, the number
of nerve cell nuclei displaying c-fos immunoreac-
tivity in the superficial dorsal horn was significantly
increased after formalin treatment, as contrasted
to normal controls. The number of c-fos-expressing
neurons in the segmentally related upper dorsal
horn was 3276 on the formalin-injected side and
571 on the control side. In contrast, perineural
application of a vinpocetine cuff (106 M) 3 days
prior to formalin treatment prevented increased
expression of c-fos in the ipsilateral, segmentally
related superficial dorsal horn. Three days after
application of a vinpocetine cuff (106 M), the
number of c-fos-expressing cells increased only to
673 on the formalin-injected side and to 572 on
the control side (Figures 4 and 5).ent L5 of the spinal cord, 1 h after unilateral application
oreactive cells was determined in the rectangular area.
tremendously as a consequence of the application of the
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In our previous studies (Knyiha´r-Csillik et al.,
2007a), we have shown that perineurally applied
vinpocetine, a derivative of Vinca minor, the
chemical structure of which bears no resemblance
either to vinblastin or to vincristin, is able to block
retrograde axoplasmic transport of NGF in periph-
eral nerves, inducing TDA of primary sensory axon
terminals in the segmentally related, ipsilateral
upper dorsal horn, which results in the depletion of
FRAP (and TMP), and in the partial depletion of SP
from the same area. Similar effects were observed
decades earlier after perineural application of
vinblastin and vincristin, two semi-synthetic deri-
vatives of Vinca major L. (Csillik et al., 1977, 1978).
Furthermore, the blockade of retrograde axoplas-
mic transport of 125I after perineural application of
vinpocetine is similar to that observed by us after
perineural application of vinblastin and vincristin
(Csillik, 1984; Csillik et al., 1985). Since transcuta-
neous iontophoresis of vincristin and vinblastin
alleviates chronic pain in postherpetic, trigeminalFigure 4. Distribution of c-fos immunoreactive nuclei in s
application of vinpocetine (106 M) on the sciatic nerve, an
Number of c-fos immunoreactive cells was determined in the
Figure 3. Number of c-fos immunoreactive cells in the
superficial dorsal horn 1 h after unilateral application of
the formalin test (black column) as contrasted to the
contralateral superficial dorsal horn (white column).and other neuralgias (Csillik and Knyiha´r-Csillik,
1986), the possibility arises that vinpocetine, if
applied by transcutaneous iontophoresis, could also
be used in the alleviation of pain.
Vinpocetine, synthetized by L+orincz et al. (1976)
from vincamine, is a Ca2+/calmodulin-dependent
phosphodiesterase 1 inhibitor (Han et al., 1999).
According to Keme´ny et al. (2005), vinpocetine,
widely used in clinical pharmacotherapy, is devoid
of any side effects. The fact that perineural
application of vinpocetine induces TDA by blockade
of retrograde axoplasmic transport in a peripheral
sensory nerve has been discussed in our previous
publication (Knyiha´r-Csillik et al., 2007a). The
question regarding the mechanism by which retro-
grade axoplasmatic transport was inhibited by
vinpocetine, remained, however, enigmatic.
Intracellular transport is known to be mediated
by microtubules (Porter and Tilney, 1965). In their
pioneering studies, Schwab et al. (1979) and
Thoenen et al. (1979) have shown that retrogradeegment L5 of the spinal cord, 3 days after perineural
d 1 h after unilateral formalin testing (apparent right).
rectangular area outlined in Figure 2.
Figure 5. Number of c-fos immunoreactive cells in the
superficial dorsal horn, 3 days after perineural applica-
tion of vinpocetine and 1 h after unilateral application of
the formalin test (black column) and in the contralateral
superficial dorsal horn (white column).
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function; therefore, blockade of retrograde axo-
plasmic transport of NGF by microtubule inhibitors
vincristin and vinblastin is reasonable. Vinpocetine,
however, is not a microtubule inhibitor; therefore,
the question arises as to how it can block retro-
grade axoplasmic transport of NGF. Recently,
however, new aspects of retrograde axoplasmic
transport have become known. Therefore, this
apparent controversy might be resolved by the
studies suggesting that retrograde propagation of
signalling complexes is due to the formation of a
unique organelle called ‘‘signalling endosome’’
(Zweifel et al., 2005) and to the membrane
trafficking protein called ‘‘pincher’’ that mediates
endocytosis (Shao et al., 2002; Valdez et al., 2005).
We assume that interactions of vinpocetine with
these recently discovered substances might under-
lie the mechanism of the blockade of retrograde
axoplasmic transport of NGF.
According to our behavioral studies, perineural
vinpocetine pre-treatment diminished the number
of flinchings, shakings and licking, and prevented
increased c-fos immunoreactivity in the ipsilateral,
segmentally related superficial dorsal horn. In-
creased expression of c-fos is a widely accepted
marker for increased neuronal activity (Morgan and
Curran, 1986; Hunt et al., 1987; Tassorelli et al.,
2005; Abe et al., 2005; Knyiha´r-Csillik et al.,
2007b). Recently, Butkevich et al. (2006) demon-
strated increased c-fos immunoreactivity in the
superficial dorsal spinal cord of rats subjected to
the painful formalin test. Decrease in the number
of flinchings, shakings and licking, and decreased
amount of c-fos immunoreactive cells in the
ipsilateral superficial dorsal horn are incontestable
signs of decreased nociception and pain.
On the basis of the observations of Musaev et al.
(1998) that prove that vinpocetine can be adminis-
tered successfully by iontophoresis, it can be
assumed that iontophoretically applied vinpocetine
might be an effective measure in alleviating
chronic neuropathic pain without any side effects.
Even though our experiments are related only to
the lower extremities, they can be rationally
extrapolated to the entire organism: a challenge
for pain clinicians.Acknowledgments
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